Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment

Reuters

2025/06/02

Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment

Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540767764"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540767764\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540767764?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540767764","market":"us","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-02 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL23xm4s:1","article_id":"2540767764","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540767764","pubTimestamp":1748863833,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference  therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7  expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule  platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","ARWR":"Arrowhead Research Corporation"},"translate_title":"Arrowhead Pharmaceuticals启动ARO-ALK7治疗肥胖的1/2a期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":0.9},"content_text":"Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment\n    \n\n        Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602644854) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}